Olga Mulas, Elisabetta Abruzzese, Luigiana Luciano, Alessandra Iurlo, Immacolata Attolico, Fausto Castagnetti, Sara Galimberti, Massimiliano Bonifacio, Mario Annunziata, Antonella Gozzini, Ester Maria Orlandi, Fabio Stagno, Gianni Binotto, Patrizia Pregno, Claudio Fozza, Maurizio Loi, Malgorzata Monika Trawinska, Fiorenza De Gregorio, Daniele Cattaneo, Francesco Albano, Miriam Iezza, Claudia Baratè, Luigi Scaffidi, Chiara Elena, Valentina Giai, Emilia Scalzulli, Massimo Breccia, Giorgio La Nasa, Giovanni Caocci
Patients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib may experience arterial occlusive events (AOEs). It is currently recommended to thoroughly assess cardiovascular risk factors before treating CML. We identified 455 consecutive CML adult patients, 335 treated with nilotinib and 120 with ponatinib; 380 patients without previous cardiovascular diseases or diabetes were stratified according to the Systematic Coronary Risk Evaluation (SCORE2) and SCORE2-Older Persons (SCORE2-OP). This updated algorithm from the European Society of Cardiology (ESC) estimates a 10-year risk of fatal and non-fatal cardiovascular diseases...
November 28, 2023: Annals of Hematology